The publication highlights the effectiveness of the device based on the combination of hemocompatibility and autoregulation PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a […]
Tag: Aeson
CARMAT Announces the First Implantation of Aeson® Within the Framework of The EFICAS Clinical Study in France
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced the first implantation of its Aeson® […]
CARMAT Announces the Resumption of Commercial Implants of its Aeson® Artificial Heart Is Now Effective
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced that the resumption of commercial implants […]
CARMAT Announces That It Has Received the Necessary Regulatory Approvals to Resume Aeson® Commercial Implants
DEKRA has provided notified body approval of all changes implemented by CARMAT PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of Aeson®, the world’s most advanced total artificial heart, designed to provide a therapeutic alternative for people suffering […]
CARMAT Announces Three Publications About Aeson® in Peer-Reviewed Scientific Journals
Clinical results confirm hemocompatibility and show absence of inflammation after Aeson® implant, with significant potential benefits for patients PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an […]
CARMAT Announces the First Implant of Its Aeson® Total Artificial Heart in the Netherlands
The implant took place at the University Medical Centre Utrecht, The Netherlands November 15, 2021 01:00 AM Eastern Standard Time PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming […]
CARMAT Receives Final Approval From the Patient Protection Committee for the Use of the Commercial Version of the Aeson® Heart in the EFICAS Study in France
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces […]
CARMAT Announces a New Commercial Implant of Its Aeson® Artificial Heart at University Medical Center Schleswig-holstein in Kiel, Germany
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the third implant of its […]
CARMAT announces the first commercial implant of its Aeson® artificial heart
The implant, performed at the Azienda Ospedaliera dei Colli hospital in Naples, Italy, represents the first sale for CARMATand paves the way for the Company’s commercial development PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the […]